Verily's revolving door to the FDA; why CAR-T cancer therapy doesn't always work

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        STAT+: At Verily, a growing line of business builds on a revolving door to the FDA By Katie Palmer Sipa via AP Alphabet spinout Verily is building technology to bolster the use of real-world evidence. It is making notable hires from the FDA to do so. Read More STAT+: CAR-T therapy doesn't work in all cancer cases. Scientists are starting to figure out why By Angus Chen Adobe Two teams of scientists identify a possible saboteur in the mix of immune cells that were engineered to help. Read More Opinion: Messaging — the unrecognized coefficient in pandemic control — matters By Jim Downs and Eleanor J. Murray Federal Art Project/Library of Congress Public health messaging helped stop the 1920s diphtheria epidemic in New York. It can do the same for the Covid-19 pandemic today. Read More Sponsor content by Alexion Pharmaceuticals The accelerated approval pathway's impact speaks for itself Without FDA's accelerated approval pathway, nearly two-thirds of new medicines developed in the last 20 years would have failed to reach patients. More than 80% of these medicines treat rare conditions. And with FDA-approved treatments for only 5% of the estimated 7,000 to 10,000 rare diseases, pathways like accelerated approval are vital to encourage rare disease drug development in the biopharmaceutical industry. Read new findings on the impact of the accelerated approval pathway here. Tuesday, October 4, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser